PYXIS ONCOLOGY INC. -

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

07 Nov 2023 15:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

27 Sep 2023 08:18:58 By Nasdaq GlobeNewswire

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

31 Aug 2023 15:01:00 By Nasdaq GlobeNewswire

Pyxis Oncology Successfully Completes Acquisition of Apexigen

23 Aug 2023 07:35:00 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

11 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Jun 2023 16:00:00 By Nasdaq GlobeNewswire

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

30 May 2023 07:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology to Acquire Apexigen

24 May 2023 05:45:00 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update

11 May 2023 06:00:01 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Mar 2023 16:00:00 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update

22 Mar 2023 05:45:00 By Nasdaq GlobeNewswire

Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors

16 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference

13 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

23 Dec 2022 15:45:00 By Nasdaq GlobeNewswire

Pyxis Oncology Announces FDA Clearance of Two IND Applications

01 Dec 2022 05:45:00 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update

01 Nov 2022 05:30:00 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Sep 2022 16:00:00 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update

15 Aug 2022 06:00:01 By Nasdaq GlobeNewswire

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Jul 2022 05:45:00 By Nasdaq GlobeNewswire

Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference

28 Jun 2022 05:35:00 By Nasdaq GlobeNewswire